Dr. Lara on Epacadostat Plus Pembrolizumab in RCC

Primo N. Lara, MD
Published: Friday, Jun 23, 2017



Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat plus pembrolizumab (Keytruda) in patients with metastatic renal cell carcinoma (RCC).

The phase Ib/II trial showed encouraging response rates and safety signals for this combination, particularly with patients who had minimally pretreated disease.

The confirmed response rate was 47%. In this study, only 17% of patients experienced grade 3 or higher toxicity, which is what is expected with single agent checkpoint inhibitor therapy.
 


Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat plus pembrolizumab (Keytruda) in patients with metastatic renal cell carcinoma (RCC).

The phase Ib/II trial showed encouraging response rates and safety signals for this combination, particularly with patients who had minimally pretreated disease.

The confirmed response rate was 47%. In this study, only 17% of patients experienced grade 3 or higher toxicity, which is what is expected with single agent checkpoint inhibitor therapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x